Clinical Trials in Legnica, Poland
10 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study of Daratumumab
Multiple Myeloma
Janssen Research & Development, LLC500 enrolled91 locationsNCT05438043
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled316 locationsNCT06103864
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled638 locationsNCT06935370
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Non-Hodgkin LymphomaBacterial InfectionsHypogammaglobulinemia+2 more
Grifols Therapeutics LLC386 enrolled62 locationsNCT05645107
Recruiting
Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Diabetes Mellitus, Type 1
Novo Nordisk A/S877 enrolled193 locationsNCT07076199
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200
Recruiting
Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
Karyopharm Therapeutics Inc244 enrolled176 locationsNCT02227251
Recruiting
Phase 4
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion
Myocardial Infarction, Acute
Wroclaw Medical University1,000 enrolled43 locationsNCT05759078
Recruiting
Not Applicable
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
Coronary Artery DiseaseAcute Myocardial Infarction
Population Health Research Institute5,100 enrolled113 locationsNCT05701358
Recruiting
Phase 2
Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
CD20-positive Acute Lymphoblastic Leukemia
Maria Sklodowska-Curie National Research Institute of Oncology124 enrolled19 locationsNCT04920968
Recruiting
Lower Silesian Orbital Atherectomy Registry (LOAR)
Efficacy, SelfSafety Issues
Regional Cardiology Center, The Copper Health Centre (MCZ),500 enrolled2 locationsNCT06451146
Recruiting
Lower Silesia Culotte Bifurcation Registry (LSCBR).
Efficacy, SelfSafety Issues
Regional Cardiology Center, The Copper Health Centre (MCZ),400 enrolled2 locationsNCT06284057
Recruiting
The Lower Silesia Shockwave Registry
Efficacy, SelfSafety Issues
Regional Cardiology Center, The Copper Health Centre (MCZ),400 enrolled2 locationsNCT05916898
Recruiting
Phase 2
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell LymphomaRelapsed Diffuse Large B Cell Lymphoma
ImmunoVaccine Technologies, Inc. (IMV Inc.)102 enrolled50 locationsNCT04920617